Fig. 4: AURKAIP1 interacted with DDX5 directly and facilitated TNBC advancement though the mediation of DDX5.
From: AURKAIP1 actuates tumor progression through stabilizing DDX5 in triple negative breast cancer
A The result of anti-AURKAIP1 immunoprecipitation followed by mass spectrometry (IP-MS) in MDA-MB-231 and BT 549 cells identified DDX5 as an interacting partner of AURKAIP1. B Co-IP assay were conducted to confirm the direct interaction of AURKAIP1 and DDX5. C Representative images of immunofluorescence assays to identify the protein localization of both AURKAIP1 and DDX5. (D–F) The expression of DDX5 was detected by western blots (D), RT-qPCR (E) and immunofluorescence assay (F) after indicated alteration of AURKAIP1 in TNBC cells. RT-qPCR (G) and western blots (H) were used to examine that whether DDX5 overexpression have an effect on AURKAIP1 expression in the indicated cells. The DDX5-rescued CCK8 (I) and transwell migration (J) assays verified that upregulated AURKAIP1 induced TNBC proliferation and migration via DDX5 mediation. Data are represented with mean ± SD from three independent experiments (*p < 0.05; **p < 0.01; ***p < 0.001, ****p < 0.0001).
